Further studies will be required to determine if similar mechanisms are responsible in part for the clinical benefit of IBAT inhibitors that was recently demonstrated in children with progressive familial intrahepatic cholestasis and Alagille syndrome (21, 22). The gene discussed is SLC10A2; the disease is Alagille syndrome.